322 related articles for article (PubMed ID: 30711994)
1. Prognostic Significance of the C-Reactive Protein-to-Albumin Ratio in Patients With Metastatic Colorectal Cancer Treated With Trifluridine/Thymidine Phosphorylase Inhibitor as Later-line Chemotherapy.
Shibutani M; Nagahara H; Fukuoka T; Iseki Y; Matsutani S; Wang EN; Maeda K; Hirakawa K; Ohira M
Anticancer Res; 2019 Feb; 39(2):1051-1057. PubMed ID: 30711994
[TBL] [Abstract][Full Text] [Related]
2. Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer.
Shibutani M; Nagahara H; Fukuoka T; Iseki Y; Wang EN; Okazaki Y; Kashiwagi S; Maeda K; Hirakawa K; Ohira M
Anticancer Res; 2020 Jul; 40(7):4157-4163. PubMed ID: 32620665
[TBL] [Abstract][Full Text] [Related]
3. Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib.
Patel AK; Duh MS; Barghout V; Yenikomshian MA; Xiao Y; Wynant W; Tabesh M; Fuchs CS
Clin Colorectal Cancer; 2018 Sep; 17(3):e531-e539. PubMed ID: 29803544
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Adjuvant Chemotherapy According to the Classification of Recurrence Risk Based on Systemic Inflammatory Markers in Patients With Liver Metastases of Colorectal Cancer.
Shibutani M; Nagahara H; Fukuoka T; Iseki Y; Hirakawa K; Ohira M
Anticancer Res; 2019 Sep; 39(9):5039-5045. PubMed ID: 31519612
[TBL] [Abstract][Full Text] [Related]
5. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
[No Abstract] [Full Text] [Related]
6. Prognostic scores for evaluating the survival benefit of regorafenib or trifluridine/tipiracil in patients with metastatic colorectal cancer: an exploratory analysis of the REGOTAS study.
Moriwaki T; Fukuoka S; Masuishi T; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Hatachi Y; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Tsuji A; Tsuchihashi K; Sakai D; Ueno H; Tamura T; Yamashita K; Shimada Y
Int J Clin Oncol; 2020 Apr; 25(4):614-621. PubMed ID: 31838590
[TBL] [Abstract][Full Text] [Related]
7. Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.
Mayer RJ; Hochster HS; Cohen SJ; Winkler R; Makris L; Grothey A
Cancer Chemother Pharmacol; 2018 Dec; 82(6):961-969. PubMed ID: 30350179
[TBL] [Abstract][Full Text] [Related]
8. Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
Tsuchihashi K; Ito M; Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Satake H; Suto T; Sugimoto N; Katsumata K; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Okuyama H; Sakai D; Ueno H; Tamura T; Yamashita K; Kishimoto J; Shimada Y; Baba E
Clin Colorectal Cancer; 2018 Dec; 17(4):e687-e697. PubMed ID: 30149986
[TBL] [Abstract][Full Text] [Related]
9. Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials.
Yoshino T; Yamazaki K; Shinozaki E; Komatsu Y; Nishina T; Baba H; Tsuji A; Tsuji Y; Yamaguchi K; Sugimoto N; Denda T; Muro K; Takayama T; Esaki T; Hamamoto Y; Moriwaki T; Shimada Y; Goto M; Nakayama N; Fujii H; Tanase T; Ohtsu A
Clin Colorectal Cancer; 2018 Dec; 17(4):e719-e732. PubMed ID: 30172759
[TBL] [Abstract][Full Text] [Related]
10. Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
Suenaga M; Schirripa M; Cao S; Zhang W; Yang D; Dadduzio V; Salvatore L; Borelli B; Pietrantonio F; Ning Y; Okazaki S; Berger MD; Miyamoto Y; Gopez R; Barzi A; Yamaguchi T; Loupakis F; Lenz HJ
Eur J Cancer; 2017 Nov; 86():197-206. PubMed ID: 28992563
[TBL] [Abstract][Full Text] [Related]
11. The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting.
Shibutani M; En W; Okazaki Y; Kashiwagi S; Fukuoka T; Iseki Y; Hirakawa K; Ohira M
Anticancer Res; 2021 Dec; 41(12):6211-6216. PubMed ID: 34848475
[TBL] [Abstract][Full Text] [Related]
12. Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
Masuishi T; Taniguchi H; Kawakami T; Kawamoto Y; Kadowaki S; Onozawa Y; Muranaka T; Tajika M; Yasui H; Nakatsumi H; Yuki S; Muro K; Omae K; Komatsu Y; Yamazaki K
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392174
[TBL] [Abstract][Full Text] [Related]
13. The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.
Chan BM; Hochster HS; Lenz HJ
Am J Health Syst Pharm; 2019 Feb; 76(6):339-348. PubMed ID: 31361848
[TBL] [Abstract][Full Text] [Related]
14. Low Skeletal Muscle Mass before Salvage-Line Chemotherapy Is a Poor Prognostic Factor in Patients with Refractory Metastatic Colorectal Cancer.
Miyamoto Y; Hiyoshi Y; Akiyama T; Kiyozumi Y; Eto K; Yohei N; Iwagami S; Baba Y; Yoshida N; Baba H
Digestion; 2019; 99(1):79-85. PubMed ID: 30554226
[TBL] [Abstract][Full Text] [Related]
15. [C-reactive protein/albumin ratio as a novel inflammation-based prognostic index for predicting outcomes of patients with colorectal cancer].
Chen YY; Zhang JH; Zhang W; Yang ZK; Luo RC; Kang SJ
Nan Fang Yi Ke Da Xue Xue Bao; 2017 May; 37(5):622-627. PubMed ID: 28539284
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan.
Ogata M; Kotaka M; Ogata T; Hatachi Y; Yasui H; Kato T; Tsuji A; Satake H
PLoS One; 2020; 15(6):e0234314. PubMed ID: 32530932
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study.
Kasi PM; Kotani D; Cecchini M; Shitara K; Ohtsu A; Ramanathan RK; Hochster HS; Grothey A; Yoshino T
BMC Cancer; 2016 Jul; 16():467. PubMed ID: 27412464
[TBL] [Abstract][Full Text] [Related]
18. RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer.
Koumarianou A; Ntavatzikos A; Symeonidis D; Vallilas C; Giannakakou M; Papaxoinis G; Xynogalos S; Boukovinas I; Demiri S; Kampoli K; Oikonomopoulos G; Samantas E; Res E; Androulakis N; Vourli G; Souglakos I; Karamouzis M
Biomedicines; 2023 Apr; 11(5):. PubMed ID: 37238938
[TBL] [Abstract][Full Text] [Related]
19. Clinical Effect of the C-Reactive Protein to Serum Albumin Ratio in Patients with Metastatic Gastric or Gastroesophageal Junction Cancer Treated with Trifluridine/Tipiracil.
Hashimoto I; Kano K; Onuma S; Suematsu H; Nagasawa S; Kanematsu K; Furusawa K; Hamaguchi T; Watanabe M; Hayashi K; Furuta M; Inokuchi Y; Machida N; Aoyama T; Yamada T; Rino Y; Ogata T; Oshima T
J Pers Med; 2023 May; 13(6):. PubMed ID: 37373912
[TBL] [Abstract][Full Text] [Related]
20. Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.
Patel AK; Abhyankar R; Brais LK; Duh MS; Barghout VE; Huynh L; Yenikomshian MA; Ng K; Fuchs CS
Oncologist; 2021 Dec; 26(12):e2161-e2169. PubMed ID: 34406678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]